Efficacy and safety of once-daily inhaled ciclesonide in adults with mild to moderate asthma: A double-blind, placebo-controlled study

Respirology

Volumn 12, Issue 4, 2007, Pages 566-572

  Adachi, Mitsuru ^a,j   Ishihara, Kyosuke ^b   Inoue, Hiroshi ^c   Kudo, Koichiro ^d   Takahashi, Kiyoshi ^e   Morita, Yutaka ^f   Masuda, Ken Ichi ^g   Takada, Yoshinori ^g   Kato, Ryuichi ^h   Miyamoto, Terumasa ⁱ  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e Department of Internal Medicine   (Japan)

^f OCHANOMIZU UNIVERSITY   (Japan)

^g TEIJIN PHARMA LIMITED   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ Clinical Research Institute   (Japan)

^j SHOWA UNIVERSITY   (Japan)

more..

Author keywords

Ciclesonide; Inhaled corticosteroid; Mild to moderate asthma; On site activation; Once daily

Indexed keywords

BECLOMETASONE; CICLESONIDE; CORTICOSTEROID; PLACEBO;

ADOLESCENT; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFLAMMATION; RHINOPHARYNGITIS; STOMACH CANCER;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEAST-SQUARES ANALYSIS; MALE; PREGNENEDIONES; SPIROMETRY; VITAL CAPACITY;

EID: 34250753801     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01111.x     Document Type: Article

References (34)

1. Makino S, Furusho K, Miyamoto T, Ohta K (eds). Pharmacologic control of asthma. Asthma prevention and management guidelines. 1998, Japan (JGL 1998): English version. Int. Arch. Allergy Immunol. 2000 121 (Suppl. 1 37 70.
2. Global initiative for asthma (GINA): global strategy for asthma management and prevention: HHLB/WHO, workshop report. Updated 2005. [Accessed 10 August 2006.] Available from URL: http://www.ginasthma.com
3. National Institutes of Health. National Asthma Education and Prevention Program. Expert panel report 2:guidelines for the diagnosis and management of asthma. NIH, 1997. NIH Publication No. 97-4051.
4. Wilson AM, Clark DJ, McFarlane L, Lipworth BJ. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. Eur. J. Clin. Pharmacol. 1997 53 : 33 7.
5. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996 51 : 262 6.
6. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J. Allergy. Clin. Immunol. 1995 96 : 571 9.
7. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 2001 345 : 941 7.
8. Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann. Allergy Asthma Immunol. 2003 90 : 646 51.
9. Toogood JH, Jennings B, Greenway RW, Chuang L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol. 1980 65 : 145 53.
10. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur. Respir. J. 1995 8 : 590 2.
11. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur. Respir. J. 2000 16 : 802 7.
12. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J. Allergy Clin. Immunol. 2004 114 : 40 7.
13. Adachi M, Morikawa A, Ishihara K. Asthma insights and reality in Japan (AIRJ). Arerugi (Jpn. J. Allergol.) 2002 51 : 411 20.
14. Dietzel K, Engelstätter R, Keller A. Ciclesonide: an on-site-activated steroid. Prog. Respir. Res. 2001 31 : 91 3.
15. Stoeck M, Riedel R, Hochhaus G, Hafner D, Masso JM et al. In-vitro and in-vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J. Pharmacol. Exp. Ther. 2004 309 : 249 58.
16. Nave R, Hummel RP, Wohlsen A, Herzog R, Zech K. The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices. Am. J. Respir. Crit. Care Med. 2004 169 : A91.
17. Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm. Pharmacol. Ther. 2005 18 : 390 6.
18. Nave R, Bethke TD, van Marle SP, Zech K. Pharmacokinetics of [14C] ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. 2004 43 : 479 86.
19. Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am. J. Ther. 2005 12 : 201 9.
20. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm. Drug Dispos. 2006 27 : 197 207.
21. Bethke TD, Boudreau RJ, Hasselquist BE, Davidson P, Leach CL et al. High lung deposition of ciclesonide in 2D- and 3D-imaging. Eur. Respir. J. 2002 20 : S38.
22. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir. Med. 2006 100 : 375 84.
23. Richter R, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J. Clin. Pharmacol. 2005 45 : 146 52.
24. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled cidesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur. J. Clin. Pharmacol. 2005 61 : 203 8.
25. Tsukioka K, ed. Peak Expiratory Flow in Normal, Healthy Japanese Subjects. Kyowa Kikaku, Tokyo, 1995.
26. Miyamoto T, Shida T, Tomioka T, Makino S, Kabe J et al. Report of the expert committee for reviewing the criteria for severity of bronchial asthma. Jpn. J. Allergol. 1994 43 : 71 80 (in Japanese).
27. Chapman KR, Patel P, D'Urzo AD, Alexander M, Mehra S et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005 60 : 330 7.
28. Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J. Allergy Clin. Immunol. 1994 94 : 676 83.
29. Pearlman DS, Noonan MJ, Tashkin DP, Goldstein MF, Hamedani AG et al. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Ann. Allergy Asthma Immunol. 1997 78 : 356 62.
30. Nathan RA, Li JT, Finn A, Jones R, Payne JE et al. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000 118 : 296 302.
31. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM et al. Issues in the use of inhaled glucocorticoids. Am. J. Respir. Crit. Care Med. 1996 153 : 1739 48.
32. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin. Ther. 2002 24 : 1 20.
33. Physicians' Desk Reference. Thomson PDR, NJ, 2005 625 9, 1494 504, 1722 4.
34. Medicines Compendium 2005. Datapharm Comms Ltd., Surrey, UK, 2005 170 2, 217 28, 943 51, 2003 10.